Your browser doesn't support javascript.
loading
Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile? / 대한배뇨장애요실금학회지
International Neurourology Journal ; : 40-46, 2016.
Article Dans Anglais | WPRIM | ID: wpr-32092
ABSTRACT

PURPOSE:

To investigate the efficacy and safety of repeated botulinum toxin type-A (BTX-A) injections for patients with drug-refractory nonneurogenic overactive bladder (NNOAB) and explore factors predictive of outcome.

METHODS:

Data were collected from all patients receiving repeated BTX-A injections for drug-refractory NNOAB between 2004 and 2012. Trigone-sparing injections were administered under sedation with antibiotic prophylaxis. Patient characteristics including age, sex, preoperative urodynamics, injection number, BTX-A dose, complications, and patient global impression of improvement (PGI-I) scores were collected. Correlations between patient factors and outcomes were assessed by using Pearson's chi-square tests.

RESULTS:

Fifty-two patients with a mean age of 67.4 years (range, 26-93 years) received 140 BTX-A injections in total; 33 (64%), 15 (29%), and 4 patients (7%) received 2, 3 to 4, and 5 to 8 injections, respectively. Mean follow-up time was 49 months (range, 9-101 months). Nine patients developed urinary tract infection; additionally, 3 patients experienced transient urinary retention. Median PGI-I score was 2 out of 7 (interquartile range [IQR], 2). For 46 patients, the PGI-I score remained stable with the administration of each injection. Pearson chi-square tests revealed that male patients or reduced bladder compliance was associated with a higher (worse) PGI-I score. Median PGI-I scores for men and women were 3 (IQR, 1) and 2 (IQR, 1), respectively; additionally, median PGI-I scores for those with normal bladder compliance and those with reduced bladder compliance were 2 (IQR, 2) and 4.5 (IQR, 1), respectively. Median PGI-I scores and complication rates were the same in the older patient (≥70 years) and younger (<70 years) patient cohorts.

CONCLUSIONS:

Efficacy is maintained with repeated BTX-A injections. Patients including the elderly show a good degree of tolerability with a low complication rate. Male patients or reduced bladder compliance is associated with poorer outcomes.
Sujets)

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Infections urinaires / Urodynamique / Vessie urinaire / Toxines botuliniques / Études de cohortes / Études de suivi / Rétention d&apos;urine / Résultat thérapeutique / Compliance / Antibioprophylaxie Type d'étude: Etude d'étiologie / Etude d'incidence / Étude observationnelle / Étude pronostique / Facteurs de risque Limites du sujet: Adulte très âgé / Femelle / Humains / Mâle langue: Anglais Texte intégral: International Neurourology Journal Année: 2016 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Infections urinaires / Urodynamique / Vessie urinaire / Toxines botuliniques / Études de cohortes / Études de suivi / Rétention d&apos;urine / Résultat thérapeutique / Compliance / Antibioprophylaxie Type d'étude: Etude d'étiologie / Etude d'incidence / Étude observationnelle / Étude pronostique / Facteurs de risque Limites du sujet: Adulte très âgé / Femelle / Humains / Mâle langue: Anglais Texte intégral: International Neurourology Journal Année: 2016 Type: Article